lifevantage corp - LFVN
LFVN
Close Chg Chg %
6.05 0.11 1.82%
Closed Market
6.16
+0.11 (1.82%)
Volume: 187.81K
Last Updated:
Dec 31, 2025, 4:00 PM EDT
Company Overview: lifevantage corp - LFVN
LFVN Key Data
| Open $6.01 | Day Range 6.00 - 6.21 |
| 52 Week Range 5.69 - 27.38 | Market Cap $76.84M |
| Shares Outstanding 12.70M | Public Float 10.60M |
| Beta 0.33 | Rev. Per Employee N/A |
| P/E Ratio 8.12 | EPS $0.82 |
| Yield 272.00% | Dividend $0.05 |
| EX-DIVIDEND DATE Dec 1, 2025 | SHORT INTEREST N/A |
| AVERAGE VOLUME 184.92K |
LFVN Performance
| 1 Week | 1.48% | ||
| 1 Month | -10.33% | ||
| 3 Months | -35.02% | ||
| 1 Year | -64.86% | ||
| 5 Years | -33.91% |
LFVN Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
2
Full Ratings ➔
About lifevantage corp - LFVN
LifeVantage Corp. engages in the identification, research, development, formulation, and sale of nutraceutical dietary supplements and personal care products. Its products include Protandim, Axio, TrueScience, PhysIQ, and Petandim. It operates through the Americas, and Asia or Pacific and Europe geographical segments. The company was founded in June 1988 and is headquartered in Lehi, UT.
LFVN At a Glance
LifeVantage Corp.
3300 North Triumph Boulevard
Lehi, Utah 84043-6477
| Phone | 1-801-432-9000 | Revenue | 228.53M | |
| Industry | Pharmaceuticals: Other | Net Income | 9.81M | |
| Sector | Health Technology | 2025 Sales Growth | 14.171% | |
| Fiscal Year-end | 06 / 2026 | Employees | 238 | |
| View SEC Filings |
LFVN Valuation
| P/E Current | 8.116 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 17.325 |
| Price to Sales Ratio | 0.743 |
| Price to Book Ratio | 4.693 |
| Price to Cash Flow Ratio | 14.30 |
| Enterprise Value to EBITDA | 10.508 |
| Enterprise Value to Sales | 0.706 |
| Total Debt to Enterprise Value | 0.072 |
LFVN Efficiency
| Revenue/Employee | 960,210.084 |
| Income Per Employee | 41,197.479 |
| Receivables Turnover | 58.165 |
| Total Asset Turnover | 3.456 |
LFVN Liquidity
| Current Ratio | 1.87 |
| Quick Ratio | 1.111 |
| Cash Ratio | 0.742 |
LFVN Profitability
| Gross Margin | 80.368 |
| Operating Margin | 5.338 |
| Pretax Margin | 5.357 |
| Net Margin | 4.29 |
| Return on Assets | 14.827 |
| Return on Equity | 32.343 |
| Return on Total Capital | 21.168 |
| Return on Invested Capital | 23.844 |
LFVN Capital Structure
| Total Debt to Total Equity | 33.711 |
| Total Debt to Total Capital | 25.212 |
| Total Debt to Total Assets | 16.229 |
| Long-Term Debt to Equity | 28.322 |
| Long-Term Debt to Total Capital | 21.181 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Lifevantage Corp - LFVN
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 206.36M | 213.40M | 200.16M | 228.53M | |
Sales Growth
| -6.28% | +3.41% | -6.20% | +14.17% | |
Cost of Goods Sold (COGS) incl D&A
| 38.10M | 43.39M | 41.44M | 44.86M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 5.05M | 5.33M | 3.58M | 3.16M | |
Depreciation
| 4.95M | 5.15M | 3.40M | 3.06M | |
Amortization of Intangibles
| 100.00K | 179.00K | 181.00K | 100.00K | |
COGS Growth
| -0.24% | +13.89% | -4.49% | +8.26% | |
Gross Income
| 168.26M | 170.01M | 158.72M | 183.67M | |
Gross Income Growth
| -7.54% | +1.04% | -6.64% | +15.71% | |
Gross Profit Margin
| +81.54% | +79.67% | +79.30% | +80.37% |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 160.69M | 165.75M | 154.39M | 171.47M | |
Research & Development
| 700.00K | 600.00K | 700.00K | 1.40M | |
Other SG&A
| 159.99M | 165.15M | 153.69M | 170.07M | |
SGA Growth
| -2.25% | +3.15% | -6.85% | +11.06% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | - | 2.21M | - |
EBIT after Unusual Expense
| 5.37M | 4.26M | 4.33M | 12.20M | |
Non Operating Income/Expense
| (669.00K) | (260.00K) | 18.00K | 44.00K | |
Non-Operating Interest Income
| - | 198.00K | 430.00K | 431.00K | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | - | 10.00K | - |
Interest Expense Growth
| - | - | -41.18% | -100.00% | - |
Gross Interest Expense
| - | - | - | 10.00K | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| 4.69M | 4.00M | 4.35M | 12.24M | |
Pretax Income Growth
| -72.78% | -14.75% | +8.78% | +181.45% | |
Pretax Margin
| +2.27% | +1.87% | +2.17% | +5.36% | |
Income Tax
| 1.57M | 1.46M | 1.41M | 2.44M | |
Income Tax - Current - Domestic
| 492.00K | 2.45M | 1.70M | 3.63M | |
Income Tax - Current - Foreign
| 1.20M | 686.00K | 984.00K | 491.00K | |
Income Tax - Deferred - Domestic
| (434.00K) | (1.70M) | (1.43M) | (1.80M) | |
Income Tax - Deferred - Foreign
| 318.00K | 28.00K | 158.00K | 119.00K | |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| 3.12M | 2.54M | 2.94M | 9.80M | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| 3.12M | 2.54M | 2.94M | 9.80M | |
Net Income Growth
| -75.80% | -18.59% | +15.63% | +233.84% | |
Net Margin Growth
| +1.51% | +1.19% | +1.47% | +4.29% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| 3.12M | 2.54M | 2.94M | 9.80M | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| 3.12M | 2.54M | 2.94M | 9.80M | |
EPS (Basic)
| 0.2421 | 0.2023 | 0.2358 | 0.8003 | |
EPS (Basic) Growth
| -73.58% | -16.44% | +16.56% | +239.40% | |
Basic Shares Outstanding
| 12.89M | 12.56M | 12.46M | 12.25M | |
EPS (Diluted)
| 0.2387 | 0.2021 | 0.2262 | 0.755 | |
EPS (Diluted) Growth
| -73.59% | -15.33% | +11.92% | +233.78% | |
Diluted Shares Outstanding
| 13.07M | 12.57M | 12.99M | 12.99M | |
EBITDA
| 12.62M | 9.59M | 7.91M | 15.36M | |
EBITDA Growth
| -46.15% | -24.05% | -17.45% | +94.05% | |
EBITDA Margin
| +6.12% | +4.49% | +3.95% | +6.72% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 14.50 | |
| Number of Ratings | 2 | Current Quarters Estimate | 0.387 | |
| FY Report Date | 03 / 2026 | Current Year's Estimate | 1.047 | |
| Last Quarter’s Earnings | 0.22 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 0.82 | Next Fiscal Year Estimate | 1.217 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 3 | 3 | 3 | 3 |
| Mean Estimate | 0.39 | 0.32 | 1.05 | 1.22 |
| High Estimates | 0.55 | 0.35 | 1.08 | 1.32 |
| Low Estimate | 0.27 | 0.30 | 1.00 | 1.15 |
| Coefficient of Variance | 37.69 | 7.78 | 3.98 | 7.46 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 2 | 2 | 1 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 0 | 0 | 0 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Lifevantage Corp - LFVN
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Lifevantage Corp - LFVN
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| May 2, 2025 | Kristen Cunningham Chief Sales Officer | 104,388 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $12.14 per share | 1,267,270.32 |
| Apr 4, 2025 | Steven R. Fife President and CEO; Director | 632,371 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $15.79 per share | 9,985,138.09 |
| Apr 4, 2025 | Kristen Cunningham Chief Sales Officer | 107,549 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $15.79 per share | 1,698,198.71 |
| Apr 4, 2025 | Kristen Cunningham Chief Sales Officer | 3,001 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 4, 2025 | Alissa Neufeld General Counsel | 94,500 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 4, 2025 | Alissa Neufeld General Counsel | 91,701 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $15.79 per share | 1,447,958.79 |
| Apr 4, 2025 | Alissa Neufeld General Counsel | 2,667 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 4, 2025 | Carl Aure Chief Financial Officer | 134,807 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 4, 2025 | Carl Aure Chief Financial Officer | 132,058 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $15.79 per share | 2,085,195.82 |
| Apr 4, 2025 | Carl Aure Chief Financial Officer | 2,401 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 4, 2025 | Julie Boyster Chief Marketing Officer | 119,493 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 4, 2025 | Julie Boyster Chief Marketing Officer | 115,517 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $15.79 per share | 1,824,013.43 |
| Apr 4, 2025 | Julie Boyster Chief Marketing Officer | 3,667 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 13, 2025 | Michael A. Beindorff Director | 44,168 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $19.54 per share | 863,042.72 |
| Feb 13, 2025 | Raymond B. Greer Director | 99,288 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $20.15 per share | 2,000,653.20 |
| Feb 13, 2025 | Cindy Latham Director | 51,348 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $20.02 per share | 1,027,986.96 |